semaglutide half-life chart results week by week: timeline from first dose to full results Semaglutide dosing guidelines for 2026

Clinical evidence for this effect is limited, and responses vary between individuals

Many people experience nausea, vomiting, diarrhea, constipation, or stomach pain

JAMA 330 (5), 454459

The today only style deals also pressure people into ordering excess inventory of a product with unknown effectiveness

Clinical Trial Results The clinical trial SURMOUNT-5 (NCT05822830) of adults with obesity who did not have type 2 diabetes demonstrated that Zepbound patients had an average weight loss of 50.3 lbs (22.8 kg), which was 20.2% of their body weight, and a 7.2-inch ( 18.4 cm) reduction in waist circumference, at 72 weeks